Decode Genetics Overview
- Founded
-
1996

- Status
-
Acquired/Merged
- Employees
-
331

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$415M
Decode Genetics General Information
Description
Operator of a biopharmaceutical company intended to offer services in analyzing and understanding the human genome. The company's technology develops and markets products to improve the treatment, diagnosis, prevention of common diseases and applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, enabling clients in the healthcare sector to market Deoxyribonucleic acid (DNA)-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases.
Contact Information
Website
www.decode.com
Formerly Known As
DGI Resolution
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- Sturlugata 8
- Reykjavik, 101
- Iceland
+354 570 0000
Decode Genetics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Merger/Acquisition | 10-Dec-2012 | $415M | 000 | 00000 | Completed | Generating Revenue |
6. Debt - General | 30-Sep-2011 | 000 | 000 | Completed | Generating Revenue | |
5. Merger/Acquisition | 15-Jan-2010 | Completed | Generating Revenue | |||
4. Bankruptcy: Admin/Reorg | 17-Nov-2009 | Completed | Bankruptcy: Admin/Reorg | |||
3. IPO | 18-Jul-2000 | 00000 | 00000 | Completed | Generating Revenue | |
2. Debt - General | Completed | Startup | ||||
1. Early Stage VC | Completed | Startup |
Decode Genetics Patents
Decode Genetics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
FR-2979545-A1 | Stilt for use as pedestrian displacement assistance device, has operating point spaced apart from attachment point, where actuation point of beam is free to approach attachment point of foot by utilizing inflection of rod | Withdrawn | 07-Sep-2011 | 000000000 | |
US-20130273543-A1 | Genetic variants useful for risk assessment of thyroid cancer | Abandoned | 21-Dec-2010 | 000000000 | |
US-20120150032-A1 | Sequence variants associated with prostate specific antigen levels | Abandoned | 13-Dec-2010 | 0000000000 | |
US-20170191134-A1 | Sequence variants associated with prostate specific antigen levels | Abandoned | 13-Dec-2010 | 0000000000 | |
US-20130224739-A1 | Genetic markers for risk management of vascular disease | Abandoned | 22-Jun-2010 | C12Q1/6883 |
Decode Genetics Executive Team (6)
Decode Genetics Signals
Decode Genetics Former Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
ARCH Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Alta Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Atlas Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
Nýsköpunarsjóður | Venture Capital | Minority | 000 0000 | 000000 0 | |
Polaris Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Decode Genetics Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 0000 | 15-Mar-2002 | 0000000000 | 000.00 | Drug Discovery | 0á00 0000 |